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INTRODUCTION 
Oral cancer refers to all malignancies arising from the 
lips, alveolus, floor of mouth, cheek, tongue, gingiva 
and pharynx [1]. It is one of the major global public 
health problems and is the sixth most common human 
malignancy with a five year mortality rate of almost 
50% [2]. This has not changed significantly over the last 
50 years [3].It is the commonest cancer in males and 
the third commonest cancer in females in India. More 
than 90% of tumours of the oral cavity are squamous 
cell carcinoma arising from the oral mucosa [4]. Squa-
mous cell carcinoma occurs mostly in men aged 45 
years and older and is associated with tobacco and al-
cohol consumption [5].A high prevalence of oral cancer 
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in India and other Asian countries has been attributed 
to the influence of region specific epidemiological fac-
tors such as tobacco and betel quid chewing[6]. Oral 
cancer is a major problem in the Indian subcontinent 
where it ranks among the top three types of cancer in 
the country [7].  
Age-adjusted rates of oral cancer in India is high i.e. 20 
per 100,000 population and accounts for over 30% of 
all cancers in the country [8]. Another alarming scenar-
io is the increasing incidence of oral squamous cell car-
cinoma (OSCC) in younger people owing to the heavy 
abuse of alcohol, tobacco and tobacco related prod-
ucts.Even though clinical diagnosis occurs via examina-
tion of the oral cavity and tongue which is easily acces-
sible by current diagnostic tools, the majority of cases 
present to a healthcare facility at later stages of cancer, 
thereby reducing chances of survival due to delay in 
diagnosis [9]. 
Tumour markers are substances present in, or pro-
duced by, a tumour itself or produced by a host in re-
sponse to a tumour that can be used to differentiate a 
tumour from normal tissue or to determine the pres-
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ence of a tumour based on measurements in blood or 
secretions [10, 11]. Tumour markers include various 
substances like cell surface antigens, cytoplasmic pro-
teins, enzymes, hormones, oncofetal antigens, recep-
tors, oncogenes and their products [10]. These sub-
stances can be found in blood, saliva, urine, stool, tu-
mour tissue, or other tissues or bodily fluids of patients 
with cancer. 
Tumour markers are very useful in monitoring the 
course of a diagnosed malignant tumour, for example 
their levels decrease in response to treatment and in-
crease when the cancer recurres or is irresponsive to 
any treatment modality. When used in combination 
with other investigations the changed levels of tumour 
markers can be extremely useful in the detection and 
diagnosis of cancer [12]. Currently biopsy is considered 
to be a gold standard diagnostic technique for diagnos-
ing oral malignancy. 
The purpose of this study was to assess that salivary CA
-125 and LDH can be used as a potential tumour mark-
ersfor early diagnosis and treatment of OSCC.  
Aim:-To assess the role of CA 125 & LDH as a tumour 
marker in Oral cancer patients. 
Objectives:- 1) To estimate the levels of salivary CA 125 
and LDH in following groups  
MATERIALS AND METHODS 
Study design:  cross sectional observational study.  
Ethics approval: This study was approved by the ethical 
committee of our institute 
Study Period: December 2015 to August 2017. 
Study location: Bharati Hospital, Pune. (Tertiary care 
centre) 
Study population: 90 random patient presenting with 
oral pathology, 30 individuals addicted to tobacco. 
And 30 individuals who are in good health without any 
addiction. 
Inclusion criteria: All patients above 18 years, attend-
ing Bharati hospital surgery OPD for Oral pathology 
were included in this study  
Exclusion criteria: Patients with a history of any other 
malignancy. Subjects with psychiatric disorders who 
can‘t give consent.  
Grouping: Group 1: 30 absolutely healthy individuals 
with no habit of tobacco chewing, smoking and alcohol.  
Group 2: 30 healthy tobacco users and smokers with-
out apparent clinical oral lesion. 
Group 3: 30 patients with proven Pre malignant lesions 
in oral cavity. 
Group 4: 30 diagnosed case of oral cancers for the first 
time.  
Group 5: 30 patients who have undergone surgery and 
coming for regular follow up and are in 3rd month after 
surgery.  
Methodology 
Under non-stimulatory conditions 5cc whole saliva 
sample was collected from each individual of all the 
groups in a wide mouth container. Saliva sample was 
immediately centrifuged at 3000 rpm for 10 minutes to 
remove squamous cells and debris. The resulting super-
natant fluid was subjected to ELISA for assessment of 
CA 125 and LDH levels. [13] 
Statistical analysis: The collected data was coded and 
entered in Microsoft Excel sheet. Mean, SD and Median 
was calculated for quantitative data. Salivary concen-
trations of CA125 in normal, premalignant lesion and 
oral squamous cell carcinoma patients were compared 
using Mann-Whitney U test. 
RESULTS 
The study covered total of 150 subjects divided into 5 
groups. Salivary sample was collected from each of 
these individuals to assess the level of CA -125 and 
LDH. Advantages of salivary sample collection were 
that it was noninvasive, easy, safe and inexpensive. The 
sample collection did not require any trained medical 
staff. It could be collected anywhere. Also, it was easy 
to store and transport to the laboratory. 
Of these 71 % were males and 29% were fe-
males.Overall higher male prevalence was seen among 
cases with pre- malignant and malignant oral cavity 
lesions. 
The mean age of the cases with pre-malignant and ma-
lignant oral cavity lesions was 51.73 years and 55.87 
years respectively. 
Also mean Salivary CA-125 was lowest in group 1 and 
highest in group 4 and the levels were seen to be re-
duced significantly in group 5 as compared to group 4.
(Table 1) 
In present study, mean Salivary LDH level was found to 
be lowest among cases of group1 while it was highest 
among cases of group 5. However there was insignifi-
cant difference seen between levels of group 4 and 
group 5. (Table 2) 
Table 1. Comparison of mean salivary CA-125 levels 
among study groups. 
 
Variables Group Mean±SD p- value 
Salivary-
CA-125 
(mg/dl) 
1 
33.00±24.
37 
Total p – value 
in all the groups 
was <0.01 
(Group1 vs 
group 2,3,4 5 
Group 2 vs 
group3,4,5 
Group 3 vs 
group 4,5 
Group 4 vs 
group 5 ) 
2 
296.67±1
61.4 
3 
809.64±5
61.7 
4 
1362.19±
523.3 
5 
888.15±3
06.1 
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Table 2. Comparison of mean salivary LDH levels 
among study groups. 
 
DISCUSSION 
Oral cancer, when found early, has an 80 to 90% surviv-
al rate. Despite this fact and great treatment advances, 
the World Health Organization has reported oral cancer 
as having one of the highest mortality ratios amongst 
other malignancies with a death rate at five years from 
diagnosis (45%) [14]. This high morbidity rate can defi-
nitely be attributed to the late diagnosis of the disease 
[15].  
Tumour markers are very useful in monitoring the 
course of a diagnosed malignant tumour, for example 
pre-treatment and subsequent serial values are essen-
tial for the evaluation of the response to the treatment 
modality with time. When used in combination with 
biopsies and other tests the detection of tumour mark-
ers in the blood can be extremely useful in the early 
detection of cancer thereby significantly improving its 
prognosis[12] .  
The present study was thus conducted to assess the 
role of Salivary CA 125 & LDH as a tumour marker in 
Oral Cavity cancer. The study included total of 150 sub-
jects, 30 each groups as mentioned earlier in Table 1. 
and 2. 
LDH represents a marker to cell death and tissue break-
down and its raised level often signifies a disease pro-
cess [16]. CA125 is a repeating peptide epitope of the 
mucin MUC16 [17,18], which promotes cancer cell pro-
liferation and inhibits anti-cancer immune responses
[19-22]. CA125 has been extensively investigated as a 
biomarker in three separate clinical scenarios as a 
screening test for the early detection of cancer, to dis-
tinguish between benign and malignant disease and to 
monitor response to therapy. 
In present study, overall higher male prevalence was 
seen among cases with pre-malignant (group3) and 
malignant (group4) oral cavity lesions whereas there 
are studies having the highest incidence of oral cancer 
in the world with significant male preponderance[23] 
just like ours.  
Variables Group Mean p- value 
Salivary 
LDH 
(mg/dl) 
1 
63.04± 
47.4 
Total p value 
in all the 
groups was 
<0.01 
(Group 1 vs 
group 3, 4, 5 
Group 2 vs  
group 3, 4, 5 
Group 3 vs 
group 4, 5) 
2 
231.67±1
96.44 
3 
786.23±4
32.67 
4 
1515.17±
765.14 
5 
1518.13±
1315.99 
The mean age of the cases with pre-malignant (group3) 
and malignant (group4) oral cavity lesions in this study 
was 51.73 years and 55.87 years respectively. Aggarwal 
R et al.[24] in their study of total 133 cases found mean 
of 50.16 years. Similar results were also reported by 
Pudasaini S et al. [25]with mean age of 51.6 years. Simi-
lar results were also observed by other authors [26,27]. 
In our study, mean Salivary LDH level was lowest 
among controls(group1) (63.04 mg/dl) while it is high-
est among cases of oral carcinoma after treatment 
(group5)(1518mg/dl )also there was insignificant differ-
ence  among cases of carcinoma before (group4)(1515 
mg/dl) and after treatment (group5)(1518.13 mg/dl).  
LDH Levels were able to differentiate between cases 
with pre malignant lesions (group3) (786.23 mg/dl) and 
healthy controls (group1) (63.04 mg/dl). Also, signifi-
cant difference was noted between healthy controls 
(group1) (63.04 mg/dl) and healthy tobacco users 
(group2) (231.67 mg/dl). A similar study was conducted 
by Shpitzer et al.[28] and it was found that salivary LDH 
was significantly higher in the patients with OSCC com-
pared to the control group (p<0.05). Nagler et al.[29] in 
their study observed raised level in both pre-malignant 
and malignant oral mucosa pathologies. Joshi et al.[30] 
in their study observed the mean lactate level in con-
trol, pre-malignant and OSCC group as 267.2 IU/L, 
519.36 IU/L and 788.73 IU/ L respectively (p<0.01). 
Shpitzer et al.[28] and Shpitzer et al.[31] also found 
total salivary LDH levels to be high in oral cancer pa-
tients. Our results are also comparable with the study 
done by Shetty et al.[32] who have reported consistent-
ly higher salivary LDH levels in oral precancer and can-
cer patients as compared to healthy controls. 
In this study, mean Salivary CA-125 level was very well 
able to distinguish between control (group1), premalig-
nant (group3) and malignant lesions (group4) with low-
est values seen among controls (group1) (33.0 mg/dl) 
followed by healthy tobacco users (group2) (296.67 
mg/dl), cases with pre malignant lesions (group3) 
(809.64 mg/dl) and it was highest among cases of oral 
carcinoma (group4) (1362.2 mg/dl). Also the levels sali-
vary CA-125 were seen to be reduced significantly post-
operatively in patients of group 5 (888.15 mg/dl) as 
compared to patients with oral malignancy in group 4
(1362.2 mg/dl) Balan et al.[13] in a similar study ob-
served the mean salivary CA 125 values of OSCC pa-
tients as 320.25 and that of control group as 33.14 
(p<0.05). Rihan M et al. [33], observed the level of sali-
vary CA-125 as 342.65 U/ml in cases of OSCC which was 
significantly increased compared with 203.65 U/ml in 
the healthy controls, (P 0.017). The authors concluded 
that salivary CA-125 can be a potential tumor marker 
for OSCC. Geng XF et al. [34] in their study also ob-
served significant difference in CA-125 levels among 
patients with OSCC than in patients with non-neoplastic 
disease and healthy controls, however contrary to our 
findings CA-125 levels were not significantly different 
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between patients with non-neoplastic  disease and 
controls. 
CONCLUSION 
These observations showed that salivary CA 125 and 
LDH has a role in early detection of oral malignancies 
and differentiating between premalignant and malig-
nant lesions. The present study was done in a limited 
population, thus needs further evaluation in larger co-
hort studies to see the role of high CA-125 and LDH 
level among tobacco chewers and its prognostic value 
in cases who quit or continued tobacco chewing and 
developed OSCC.  
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